Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#91 / 200 Total
TFFP - Tff Pharmaceuticals Inc - Stock Price Chart
CompanyTff Pharmaceuticals Inc
Market Cap5.89MEPS (ttm)-10.21
P/E-EPS this Y60.34%
Forward P/E-EPS next Y17.23%
PEG-EPS past 5Y-13.86%
P/S-EPS next 5Y-
P/B0.90EPS Q/Q50.69%
Dividend-Sales Q/Q-
Insider Own5.80%Inst Own11.44%
Insider Trans0.00%Inst Trans9.29%
Short Float5.05%EarningsMay 14/a
Analyst Recom1.00Target Price17.00
Avg Volume43.42K52W Range1.54 - 15.95
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARLSON CAPITAL L P10% OwnerAug 16 '23Sale0.391,0003925,064,000Aug 17 05:29 PM
Weisman Harlan FPresident and CEOAug 15 '23Buy0.25600,000150,000814,615Aug 15 08:00 AM
Mikhak ZamanehChief Medical OfficerAug 15 '23Buy0.25120,00030,000135,000Aug 15 08:00 AM
MILLS ROBERT SDirectorAug 15 '23Buy0.2540,00010,00055,980Aug 15 08:00 AM
ROCAMBOLI STEPHENDirectorAug 15 '23Buy0.2520,0005,00036,000Aug 15 08:00 AM
MRKR - Marker Therapeutics Inc - Stock Price Chart
CompanyMarker Therapeutics Inc
Market Cap42.01MEPS (ttm)-1.63
P/E-EPS this Y-74.29%
Forward P/E-EPS next Y18.65%
PEG-EPS past 5Y52.24%
P/S12.65EPS next 5Y-
P/B3.56EPS Q/Q52.81%
Dividend-Sales Q/Q-73.72%
Insider Own27.74%Inst Own10.60%
Insider Trans0.00%Inst Trans-44.88%
Short Float0.92%EarningsMay 15/a
Analyst Recom1.00Target Price11.00
Avg Volume20.07K52W Range2.40 - 9.68
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
TENX - Tenax Therapeutics Inc - Stock Price Chart
CompanyTenax Therapeutics Inc
Market Cap5.92MEPS (ttm)-24.54
P/E-EPS this Y74.37%
Forward P/E-EPS next Y53.30%
PEG-EPS past 5Y70.74%
P/S-EPS next 5Y-
P/B0.48EPS Q/Q74.25%
Dividend-Sales Q/Q-
Insider Own4.01%Inst Own16.25%
Insider Trans0.00%Inst Trans-
Short Float0.34%EarningsMay 14/b
Analyst Recom1.00Target Price32.50
Avg Volume32.93K52W Range2.77 - 61.20
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.
INDO - Indonesia Energy Corp Ltd - Stock Price Chart
CompanyIndonesia Energy Corp Ltd
IndustryOil & Gas E&P
Market Cap28.36MEPS (ttm)-0.26
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S8.03EPS next 5Y-
P/B1.92EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own53.26%Inst Own1.17%
Insider Trans0.00%Inst Trans-62.92%
Short Float1.26%Earnings-
Analyst Recom1.00Target Price10.00
Avg Volume2.22M52W Range2.03 - 6.65
Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.
OBIO - Orchestra BioMed Holdings Inc - Stock Price Chart
CompanyOrchestra BioMed Holdings Inc
Market Cap246.59MEPS (ttm)-1.46
P/E-EPS this Y-7.06%
Forward P/E-EPS next Y-6.82%
PEG-EPS past 5Y-
P/S111.08EPS next 5Y-
P/B4.31EPS Q/Q4.93%
Dividend-Sales Q/Q-46.74%
Insider Own42.40%Inst Own36.48%
Insider Trans0.03%Inst Trans-31.90%
Short Float3.70%EarningsMay 13/a
Analyst Recom1.00Target Price16.33
Avg Volume60.54K52W Range4.22 - 11.69
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded on May 25, 2020 and is headquartered in New Hope, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Little William ReedSee RemarksMay 30 '24Buy7.004,00028,000307,859Jun 03 04:15 PM
NAMS - NewAmsterdam Pharma Company NV - Stock Price Chart
CompanyNewAmsterdam Pharma Company NV
Market Cap1.77BEPS (ttm)-
P/E-EPS this Y-17.03%
Forward P/E-EPS next Y31.69%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.28EPS Q/Q-2124.81%
Dividend-Sales Q/Q-
Insider Own55.79%Inst Own38.08%
Insider Trans-0.34%Inst Trans3.24%
Short Float0.62%EarningsMay 09/b
Analyst Recom1.00Target Price34.71
Avg Volume173.97K52W Range5.63 - 26.35
Jun-11-24 08:00AM NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office (GlobeNewswire)
Jun-07-24 04:01PM NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 08:00AM NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 08:00AM NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings (GlobeNewswire)
May-09-24 08:00AM NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results (GlobeNewswire)
May-03-24 04:01PM NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 (GlobeNewswire)
Apr-09-24 08:00AM NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Apr-01-24 08:00AM NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer (GlobeNewswire) -9.64%
Mar-25-24 08:00AM NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress (GlobeNewswire)
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davidson Michael H.Chief Executive OfficerJun 20 '24Buy17.265,00086,308204,784Jun 24 08:30 AM
Topper James NDirectorMar 26 '24Buy21.508,429181,2243,008,429Mar 28 04:30 PM
Kastelein Johannes Jacob PieteChief Scientific OfficerMar 26 '24Sale21.50190,4764,095,2340Mar 27 04:30 PM
LANGE LOUIS GDirectorFeb 13 '24Buy19.005,00095,00024,878Feb 21 05:00 PM
VALN - Valneva SE ADR - Stock Price Chart
CompanyValneva SE ADR
Market Cap544.03MEPS (ttm)-0.38
P/E-EPS this Y103.85%
Forward P/E-EPS next Y-1483.43%
PEG-EPS past 5Y-
P/S3.28EPS next 5Y-
P/B2.65EPS Q/Q427.43%
Dividend-Sales Q/Q-1.12%
Insider Own0.38%Inst Own0.65%
Insider Trans0.00%Inst Trans-
Short Float0.11%EarningsMay 07/b
Analyst Recom1.20Target Price20.10
Avg Volume10.58K52W Range6.58 - 16.49
Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.
CUE - Cue Biopharma Inc - Stock Price Chart
CompanyCue Biopharma Inc
Market Cap71.50MEPS (ttm)-1.07
P/E-EPS this Y12.43%
Forward P/E-EPS next Y0.21%
PEG-EPS past 5Y10.55%
P/S10.19EPS next 5Y-
P/B2.38EPS Q/Q14.99%
Dividend-Sales Q/Q818.18%
Insider Own0.92%Inst Own35.85%
Insider Trans0.00%Inst Trans-6.78%
Short Float9.02%EarningsMay 09/a
Analyst Recom1.00Target Price9.40
Avg Volume282.00K52W Range1.26 - 4.89
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suri AnishPRESIDENT AND CSOAug 25 '23Buy2.764,00011,040135,638Aug 29 04:08 PM
PASSERI DANIEL RCHIEF EXECUTIVE OFFICERAug 14 '23Buy2.863,0008,580134,578Aug 16 04:07 PM
STEM - Stem Inc - Stock Price Chart
CompanyStem Inc
IndustrySoftware - Infrastructure
Market Cap198.83MEPS (ttm)-1.45
P/E-EPS this Y6.97%
Forward P/E-EPS next Y54.29%
PEG-EPS past 5Y-438.13%
P/S0.47EPS next 5Y-
P/B0.53EPS Q/Q-58.17%
Dividend-Sales Q/Q-62.21%
Insider Own6.95%Inst Own64.60%
Insider Trans-7.30%Inst Trans2.03%
Short Float21.85%EarningsMay 02/a
Analyst Recom2.33Target Price3.67
Avg Volume4.42M52W Range1.08 - 7.78
Stem, Inc. engages in the provision of an energy storage system, hardware, ongoing software platform and professional services, and solar asset performance monitoring and control. The company was founded in 2009 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cunningham GerardDirectorJun 07 '24Option Exercise0.0012,138012,138Jun 10 04:13 PM
Daley AdamDirectorJun 07 '24Option Exercise0.0023,4890130,760Jun 10 04:13 PM
TYSON LAURA DDirectorJun 07 '24Option Exercise0.0023,489049,511Jun 10 04:13 PM
Woodward JaneDirectorJun 07 '24Option Exercise0.0023,489049,511Jun 10 04:12 PM
Birns Ira MDirectorJun 07 '24Option Exercise0.0024,184024,184Jun 10 04:14 PM
BAOS - Baosheng Media Group Holdings Ltd - Stock Price Chart
CompanyBaosheng Media Group Holdings Ltd
IndustryAdvertising Agencies
Market Cap2.83MEPS (ttm)-11.44
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.82EPS next 5Y-
P/B0.07EPS Q/Q99.79%
Dividend-Sales Q/Q243.44%
Insider Own41.14%Inst Own0.00%
Insider Trans0.00%Inst Trans-79.63%
Short Float0.97%Earnings-
Analyst Recom-Target Price-
Avg Volume12.97K52W Range1.61 - 11.29
Baosheng Media Group Holdings Ltd. engages in the provision of online marketing solutions. It offers advertising optimization services and facilitates the deployment of online ads of various forms such as search ads, in-feed ads, mobile app ads and social media marketing ads. It operates as a search engine marketing platform which includes the promotion of websites by increasing their visibility in search engine results pages and search-related products and services. The company was founded by Wenxiu Zhong in 2014 and is headquartered in Beijing, China.